EonLabs

Eon Labs was a prominent American generic pharmaceutical company that specialized in the development and manufacture of complex generic prescription drugs. The company established a strong market presence by focusing on difficult-to-manufacture oral solid dosage forms across therapeutic categories such as cardiovascular, central nervous system, and anti-infectives. Eon Labs was particularly noted for its successful generic versions of high-volume drugs like bupropion and cyclosporine. In 2005, the company was acquired by Novartis for approximately 2.6 billion USD and integrated into its Sandoz generics division. This acquisition, combined with the purchase of Hexal AG, solidified Sandoz's position as a global leader in the generics industry. The company operated major facilities in New York and North Carolina, maintaining a reputation for high-quality manufacturing standards.